M Dougados, J Braun, S Szanto, et al. Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebocontrolled study (SPINE). Ann Rheum Dis 2011;70:799–804 doi:10.1136/ard.2010.139261. The data published for ASDAS-CRP status at W12 in Table 2 is incorrect. The data provided was the % of patients with changes during the study and not the % of patients at the end of the study. The correct table appears below:
Table 2.
Responder criteria after 12 weeks of therapy by treatment group
| Treatment group | |||
|---|---|---|---|
| Responder criteria | Placebo (n=43) | Etanercept (n=39) | p value |
| ASAS20 | 14 (33%) | 25 (67%) | 0.003 |
| ASAS40 | 10 (23%) | 17 (44%) | 0.053 |
| ASAS5/6 | 2 (5%) | 8 (21%) | 0.044 |
| ASAS partial remission | 2 (5%) | 7 (18%) | 0.073 |
| BASDAI 50 | 10 (23%) | 18 (46%) | 0.031 |
| ASDAS-CRP changes (W12-baseline) | |||
| ASDAS ≥1.1 (minimally important improvement) | 7 (17.1) | 25 (64.1) | <0.0001 |
| ASDAS ≥2.0 (major improvement) | 1 (2.4) | 15 (38.5) | <0.0001 |
| ASDAS-CRP status at W12 | |||
| ASDAS <1.3 | 2 (4.7%) | 5 (12.8%) | 0.249 |
| ASDAS <2.1 | 5 (11.6%) | 16 (41.0%) | 0.005 |
ASAS = Ankylosing Spondylitis Activity Score; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index, ASDAS = Ankylosing Spondylitis Disease Activity Score